Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

FCB Health Adds Kim Barke as Group Creative Director to Lead Oncology Accounts

NYC-based FCB Health appointed Kim Barke to the role of group creative director to lead its oncology accounts.

Read More »

Birth weight may impact intelligence throughout life

Being born at below-normal weight is associated with a lower intelligence quotient (IQ) not only in childhood and young adulthood, but even at age 50, according to a new study from Denmark.

Read More »

Biogen Acquires Remedy Pharmaceuticals’ Cirara

Remedy Pharmaceuticals announced that Biogen completed an asset purchase of its Phase 3 candidate, Cirara.

Read More »

India’s drug pricing regulator clamps down on drug cocktails

India’s drug pricing regulator has demanded explanations from 65 domestic and global drugmakers for selling new forms of essential diabetes and antibiotic drugs without its approval.

Read More »

Democratic attorneys general seek to intervene in Obamacare case

More than a dozen Democratic attorneys general sought to intervene to defend a key part of the Obamacare healthcare law – subsidy payments to insurance companies – which is under threat in a court case.

Read More »

GlycoMimetics Stock Takes Off on Positive Phase II Leukemia Data, Breakthrough Tag

Rockville, Mary.-based GlycoMimetics’ shares jumped dramatically on the news of positive interim Phase II data for GMI-1271 for acute myeloid leukemia.

Read More »

Teva Cuts Another 500 Jobs, May Hire CEO Who Isn’t Israeli

As Teva Pharmaceutical narrows down its candidate for a new chief executive officer, the company is shuttering a plant in Hungary and laying off 500 employees, according to reports.

Read More »

Shire’s Lanadelumab Wows in Phase III Study

Shire’s 2015 bet on Dyax and its experimental drug to treat the rare illness, hereditary angioedema (HAE), is paying off. The company revealed stellar Phase III data for lanadelumab that could transform the way HAE patients are treated.

Read More »

FDA Approves Kalydeco for More Than 900 People Ages 2 and Older with Cystic Fibrosis Who Have Certain Residual Function Mutations

Vertex Pharmaceuticals Incorporated announced that the U.S. Food and Drug Administration approved Kalydeco (ivacaftor) for use in people with cystic fibrosis ages 2 and older who have one of 23 residual function mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

Read More »

FDA clinical hold on Concert’s hair loss drug

Concert Pharmaceuticals Inc. said the U.S. FDA imposed a clinical hold on a trial testing the company’s drug to treat alopecia areata, a type of hair loss.

Read More »

India’s drugmakers need more time to meet international standards: industry group

India’s big drugmakers will need at least five more years to improve their manufacturing standards and data reliability to a level demanded by international regulators, said a senior industry official.

Read More »

More than half of world’s deaths still have no recorded cause: WHO

More than half of all deaths have no recorded cause, making effective health monitoring and policymaking far more difficult, the World Health Organization (WHO) said.

Read More »

J&J Plans 10 Blockbuster Approvals by 2021

In meeting with industry analysts, J&J indicated it expects to have 10 new products approved between 2017 and 2021 that have blockbuster potential.

Read More »

Amazon Hiring to Break Into the Pharmaceuticals Business

Amazon is reportedly looking for a new venture – in the pharmaceutical market. CNBC reported that for the past few years the company has been exploring the multi-billion industry, but has not yet made a move. However, that appears to be changing.

Read More »

Bayer gets FDA priority review for blood cancer drug

German drugmaker Bayer won the U.S. Food and Drug Administration’s priority review status for an experimental drug for a difficult to treat type of blood cancer, bolstering its development pipeline.

Read More »

FDA warns of foot, leg amputations with J&J diabetes drug

Johnson & Johnson is required to add new warnings to its diabetes drug Invokana about the risk of foot and leg amputations, the U.S. Food and Drug Administration said.

Read More »

New Study Finds High Prescription Drug Costs Are Not Driving Up U.S. Healthcare Costs

It’s easy for politicians and consumers to rage about the high price of prescription drugs, but Wayne Winegarden, Pacific Research Institute’s senior fellow in business and economics, said those prices are not to blame for the high cost of healthcare in the United States.

Read More »

Novelion CEO quits Novo Nordisk board due to NASH conflict

Danish drugmaker Novo Nordisk said the chief executive of Canadian biotech company Novelion Therapeutics had left its board with immediate effect due to “a potential conflict of interest.”

Read More »

Unlocking the Mystery of Multiple Sclerosis With Tech

What if a single smartphone app could help solve the enigma of multiple sclerosis (MS) and move new treatments ahead at lightning speed? That was the bold idea that led Keck Medicine of USC neurologist Daniel Pelletier, MD, professor of neurology at the Keck School of Medicine of USC and division chief of the Neuro-Immunology and USC Multiple Sclerosis Center, to develop myMS – the world’s first smartphone app capable of collecting large amounts of clinical, imaging and genetic data for people with MS. Enrollment is now under way for a pilot study of the app.

Read More »

X-Chem, Vertex Enter into Collaboration

X-Chem announced a collaboration with Vertex for the discovery of small-molecule leads against validated targets for severe, genetic diseases.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2018 Focus: Top 50 Pharma, Company of the Year and more!


Ad Right Bottom